BIOE Stock — Bio Essence Corp

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 14, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.70

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −65%

below

Price vs 50-day avg −1%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 30%

mid-range

Momentum

relative strength

Weak

1-month return +1%

trailing

6-month return −21%

trailing

YTD return +217%

this year

Relative strength −34%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $0 › 200d $1 — 200d above 50d

Institutional flow Flat

No 13F holder data

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.00% of float · ▼ -52.5% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

No 13F holder history

Fundamentals

Excellent

Revenue growth +486%

Y/Y

Gross margin 75%

expanding

EPS growth 0%

Y/Y

Free cash flow $1.6M

Quant / Vol

risk profile

Very High

Volatility 402%

annualized · 1-yr

Max drawdown −99%

past year

ATR 23.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

2 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−65% Bearish

Price vs 50-day avg

−1% Neutral

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

30% Neutral

Market signals — smart money & positioning

Bullish · 1 of 6

Trend (MA cross) No cross

50d $0 › 200d $1 — 200d above 50d

Institutional flow Flat

No 13F holder data

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.00% of float · ▼ -52.5% MoM · 1.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

No 13F holder history

Price context

position in its 52-week range

Range low $0 Now $0 · 30% Range high $1

vs 200-day avg -65% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BIOE Bio Essence Corp this stock	$10.22M	+216.7%	+485.8%	—	0.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$66.37B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$57.58B	+15.3%	—	—	0.1%
GALDY Galderma Group AG/ADR	$49.38B	-0.1%	—	—	0.0%
HLN Haleon plc	$44.46B	-0.8%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Short & Settlement

Short Interest Falling

Shares short

2.5K

Days to cover: 1.0d
Change: -2.8K sh

View

Short Volume

Short vol %

100%

As of: May 12, 2026

Short Total

View

Off-Exchange

Off-exchange %

100.0%

Week of: Jun 22, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$1.9M

Net income (FY): $896.2K
EPS diluted: $-0.03

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 14, 2026
This year: 5

View

Proposed Sales

Value

$104.5K

Shares: 1.5K
Filed: Oct 9, 2024

View

	5D	20D	120D	MTD	YTD
BIOE	-29.6%	+0.5%	-20.8%	-29.6%	+216.7%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	-30.1%	-2.5%	-34.3%	-32.6%	+203.9%

BIOE · Bio Essence Corp

Price & Indicators

Up next

Equibles Rating

Technicals

Versus peers

At a glance

Performance